All Brands Owned by Perrigo Company plc

Who owns Perrigo Company plc?
Perrigo Company plc is a publicly traded corporation listed on NYSE under ticker PRGO. The company is legally domiciled in Ireland as a public limited company. Ownership is distributed among institutional investors including Vanguard Group, BlackRock, and other index fund managers. No single shareholder holds a controlling stake. The company moved its tax domicile to Ireland in 2013 through the acquisition of Elan Corporation.

What does Perrigo make?
Perrigo manufactures over 18,600 products including over-the-counter medicines, nutritional products, infant formula, and personal care items. The company is the largest store-brand OTC pharmaceutical manufacturer in the United States. Its products appear on shelves under retailer private labels including Walmart's Equate, CVS Health, and Walgreens Brand. Perrigo also owns branded products including Rembrandt oral care and Good Sense OTC medicines.

Why is Perrigo headquartered in Ireland?
Perrigo moved its tax domicile to Ireland in 2013 through a $8.6 billion acquisition of Elan Corporation, an Irish biotechnology company. The transaction was a tax inversion, reducing Perrigo's effective tax rate from around 30 percent to the high teens by taking advantage of Ireland's 12.5 percent corporate tax rate. The company's US operations remain based in Allegan, Michigan. The inversion drew political criticism but was completed legally.

What was the Mylan takeover attempt?
In 2015, Mylan N.V. launched a hostile tender offer to acquire Perrigo for approximately $75 in cash and 2.3 Mylan shares per Perrigo share. The Perrigo board unanimously rejected the offer as inadequate. The FTC required Mylan to divest rights to seven generic drugs as a condition. Mylan failed to secure enough tendered shares, and the deal collapsed. Some shareholders later questioned the decision as Perrigo's stock declined.

What is the Three-S plan?
The Three-S plan is CEO Patrick Lockwood-Taylor's restructuring strategy, consisting of Stabilize, Streamline, and Strengthen. Stabilize involves fixing the store-brand business and infant formula operations. Streamline involves divesting non-core assets, including the announced sale of the Dermacosmetics business and the strategic review of infant formula. Strengthen involves investing in high-performing OTC categories and implementing a new commercial operating model.

What were Perrigo's FY2025 financial results?
Perrigo reported FY2025 net sales of $4.25 billion, down 2.8 percent year over year. The company recorded a reported operating loss of $1.12 billion due to a $1.36 billion goodwill impairment charge. Reported diluted EPS was negative $10.12. However, adjusted operating income was $622 million, up 2.3 percent, and adjusted EPS was $2.75, up 7 percent. Operating cash flow was $239 million, and year-end cash was $532 million.

What is happening with Perrigo's infant formula business?
On November 5, 2025, Perrigo announced a strategic review of its infant formula business. The business generated approximately $360 million in net sales in 2025, less than 10 percent of total annual net sales. The review will assess a full range of alternatives including a potential sale. CEO Patrick Lockwood-Taylor said the external environment had changed, making infant formula less strategic alongside the company's OTC businesses. The review is ongoing as of August 2026.